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Abstract 
Objectives. To investigate the dynamics of response of synovitis to interleukin (IL)-
17A inhibition with secukinumab in patients with active psoriatic arthritis (PsA) using 
Power Doppler ultrasound. 
Methods. The randomised, placebo-controlled, Phase III ULTIMATE study enrolled 
PsA patients with active ultrasound synovitis, and clinical synovitis and enthesitis 
having an inadequate response to conventional disease-modifying anti-rheumatic 
drugs (DMARDs) and naïve to biologic DMARDs. Patients were randomly assigned 
to receive either weekly subcutaneous secukinumab (300 or 150 mg according to 
the severity of psoriasis) or placebo followed by 4-weekly dosing thereafter. The 
primary outcome was the mean change in the ultrasound Global European League 
Against Rheumatism and Outcome Measures in Rheumatoid Arthritis Clinical Trials 
Synovitis Score (GLOESS) from baseline to Week 12. Key secondary endpoints 
included American College of Rheumatology 20 and 50 responses.
Results: Of the 166 patients enrolled, 97% completed 12 weeks of treatment 
(secukinumab, 99%; placebo, 95%). The primary endpoint was met, and the adjusted 
mean change in GLOESS was higher with secukinumab than placebo (−9 [0.9] vs −6 
[0.9], difference [95% CI]: −3 [−6; −1]; one-sided P=0.004) at Week 12. The difference 
in GLOESS between secukinumab and placebo was significant as early as one week 
after initiation of treatment. All key secondary endpoints were met. No new or 
unexpected safety findings were reported.
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Conclusion: This unique ultrasound study shows that apart from improving the 
signs and symptoms of PsA, IL-17A inhibition with secukinumab leads to a rapid 
and significant reduction of synovitis in PsA patients.
Trial registration: ClinicalTrials.gov; NCT02662985
Key messages: 
 Importance of GLOESS using Power Doppler ultrasound (PDUS) for detecting 
synovitis in RA has been established.
 ULTIMATE is the first RCT to show the applicability of GLOESS using PDUS in 
PsA.
 The GLOESS results confirm rapid and early response to secukinumab on 
synovitis in PsA.
Key words: PsA, Power Doppler ultrasound, OMERACT, GLOESS, Clinical outcome, 
Responsiveness, Synovitis, Joints, Secukinumab, biological DMARDs.
Word count: 3054




































































atology/keab628/6370966 by guest on 21 O
ctober 2021
    Secukinumab in PsA: PDUS assessment
5
Introduction
Psoriatic arthritis (PsA) is characterised by inflammation of synovial membranes and 
entheseal sites leading to pain, structural damage, impairment of physical function and 
quality of life [1–5]. Abrogation of inflammation in the joints is a central goal for the 
treatment of PsA, like in any other form of inflammatory arthritis. However, to date the 
effects of drug therapy on disease are usually measured indirectly, through assessing 
the impact on signs and symptoms of disease, rather than directly assessing 
inflammation at joint level. Hence, little is known about the dynamic effect of disease 
modifying anti-rheumatic drugs (DMARDs) on synovitis. 
Ultrasound in B-mode combined with Power Doppler (PD; the association named 
PDUS), permits visualisation of both morphological and functional changes of synovium 
[6, 7]. The European League Against Rheumatism (EULAR) and the Outcome 
Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) have recently 
standardised the use of PDUS for detecting synovitis and developed a composite 
scoring system at joint and patient level: the Global EULAR-OMERACT Synovitis Score 
(GLOESS), which has shown high responsiveness to treatment and excellent reliability 
in rheumatoid arthritis (RA) patients [8–11], suggesting the possibility to be used to 
monitor treatment response in inflammatory arthritis.
Secukinumab, a human monoclonal antibody that directly inhibits interleukin 
(IL)-17A, has demonstrated sustained efficacy on signs and symptoms, inhibition of 
structural damage progression, and a favourable long-term safety profile in patients with 
PsA over 5 years [12–14], however, little is known on its direct effect on synovitis (and 
enthesitis) and the dynamics of such response. To investigate this, we initiated the 
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ULTIMATE study, which is the first PDUS-based randomised placebo-controlled trial in 
PsA that primarily focussed on synovial responses rather than on signs and symptoms 
of disease. Hence, the primary aim of the ULTIMATE study was to evaluate whether 
treatment with secukinumab inhibits synovitis, as measured by PDUS, in patients with 
active PsA who failed conventional synthetic DMARDs (csDMARDs) therapy and were 
naïve to biological DMARDs (bDMARDs). Herein, we present the primary efficacy data 
of secukinumab on synovitis in patients with active PsA. 
Methods
Patients and study design
Biologic-naïve patients (aged ≥18 years) with a diagnosis of PsA for at least 6 months, 
fulfilling the CASPAR criteria, and having an inadequate response to csDMARDs and 
an active disease based on tender joint count (TJC) ≥3 of 78 joints and swollen joint 
count (SJC) ≥3 of 76 joints were considered eligible for this study. In addition, patients 
had to present active PDUS synovitis according to a pre-defined cut-off (Supplementary 
Figure S1 and Table S1, available at Rheumatology online) at screening and baseline 
and at least one clinical enthesitis at screening and baseline. Patients could continue to 
receive methotrexate, glucocorticoids, and nonsteroidal anti-inflammatory drugs 
(NSAIDs) at a stable standard dose from 1-month prior to screening to 24 weeks 
(Supplementary Figure S2, available at Rheumatology online).
Key exclusion criteria included evidence of an ongoing infection or malignant 
process; prior treatment with bDMARDs, including tumor necrosis factor inhibitors; 
active ongoing inflammatory conditions other than PsA; active systemic infection within 
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2 weeks before randomisation; history of ongoing, chronic, or recurrent infectious 
disease or evidence of tuberculosis infection; known infection with human 
immunodeficiency virus or hepatitis B or C at screening or randomisation; and history of 
lymphoproliferative disease, any known malignancy, or malignancy of any organ system 
within the past 5 years. Detailed inclusion and exclusion criteria are listed in the 
Supplementary Table S1, available at Rheumatology online. 
ULTIMATE (NCT02662985) was a multicentre, randomised, double-blind, 
placebo-controlled, 52-week Phase III study (Supplementary Figure S2, available at 
Rheumatology online). The study was initiated on August 22, 2016 (first patient, first 
visit), and conducted across 37 active sites in 17 countries. This study consisted of a 1- 
to 4-week screening phase, followed by a 12-week, double-blind, placebo-controlled 
treatment period (TP 1; baseline to Week 12); a 12-week open-label period (TP 2; Week 
12 to Week 24); a 6-month, open-label extension period (TP 3; Week 24 to Week 52); 
and a 12-week safety follow-up period (Week 52 to Week 64; Supplementary Figure S2, 
available at Rheumatology online).
Enrolled patients were randomised (1:1) using Interactive Response Technology 
(IRT) to receive either subcutaneous secukinumab (300 mg or 150 mg) or placebo 
weekly followed by 4-weekly dosing at Weeks 4 and 8 in a double-blind manner 
(Supplementary Figure S2, available at Rheumatology online). Patients received 
secukinumab 300 mg or 150 mg according to the severity of skin disease. The open-
label phase started at Week 12 (TP 2), and all patients (including the placebo group) 
received secukinumab 300 mg or 150 mg depending on the skin severity through IRT 
every 4 weeks until Week 52 in an open-label manner. Patients, study centre personnel 
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(including ultrasound and clinical investigators), and data analysts were fully blinded to 
the treatment assigned to patients at randomisation for the first 12 weeks of the study 
(TP 1). The ultrasound and clinical investigators remained blinded from each other until 
the final database lock. 
The study protocol and its amendments were reviewed and approved by the 
independent ethics committee or institutional review board for each participating centre. 
The study was conducted according to the International Council for Harmonisation (ICH) 
E6 Guideline for Good Clinical Practice (GCP) that has its origin in the Declaration of 
Helsinki [15]. Written informed consent was obtained from all enrolled patients. Data 
were collected in accordance with the GCP guidelines by the study investigators and 
analysed by the sponsor.
Assessment of joints by ultrasound
PDUS evaluation was performed at screening; baseline; and Weeks 1, 2, 4, 6, 8, 
and 12. The following 24 joints were evaluated bilaterally: metacarpophalangeal (MCP) 
joints 1 to 5, proximal interphalangeal (PIP) joints 1 to 5, metatarsophalangeal (MTP) 
joints 1 to 5, distal interphalangeal (DIP) joints 2 to 5, wrists, elbows, shoulders 
(glenohumeral), knees and ankles (tibiotalar). The joints were scanned at each visit 
from the dorsal aspect, with the joint in a neutral position, except for the knee, which 
was examined in a flexed position (30°). All recesses of each joint were scanned, and 
the detection of maximal grading of PDUS synovitis in one of these recesses 
determined the final grade of the joint.
All PDUS evaluations were performed at each site by an independent examiner, 
expert in musculoskeletal ultrasound, with more than 5 years of experience, and blinded 
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to the clinical evaluation. To ensure homogeneity of PDUS synovitis scoring, all 
ultrasound investigators completed an extensive 2-day training session, including 
examination of patients with PsA. In addition, ultrasound settings were not changed 
during the study, standardised joint and probe positions were used, and software was 
not upgraded. Centres were advised to create a fixed study setting to be used at each 
evaluation.
Medium- to high-level ultrasound machines (ESAOTE, Acuson, Logic Series 9, 7 
and enext GE, Siemens or other, such as Toshiba Xario 200, Toshiba Aplio [300, 400], 
Aloka Arietta V70, and Samsung HS60) were used, which employed high frequency 
(12–18 MHz) transducers. Doppler parameters were adjusted according to the device 
used (range of pulse repetition frequency 400–800 Hz; Doppler frequency 7–14.1 MHz).
PDUS synovitis was defined according to the EULAR-OMERACT definition as a 
hypoechoic synovial hypertrophy (SH) detected in B-mode, which may show PD signal. 
At each visit, PDUS synovitis was graded semi-quantitatively (0 to 3) according to the 
EULAR-OMERACT PDUS composite score (Table 1) [8, 11]. In addition, single 
components of this composite score (i.e. hypoechoic SH and PD synovial signal) were 
scored separately at each visit. 
The GLOESS for the 24 paired joints was calculated as the sum of each PDUS 
composite score for all joints examined, giving a potential score ranging from 0 to 144. 
As previously reported, GLOESS incorporates both B-mode and PD measures of 
synovitis and allows to evaluate changes in the activity and morphology of synovitis. To 
help in grading severity, an atlas with examples of B-mode and PD grading for all joints 
examined was available in each centre. 
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All images were recorded, anonymised and sent for central reading for the first 
patient enrolled at each centre to allow a verification of the consistent scoring across 
sites. Training session and central reading of the images collected from the first 
included patient enrolled in each site were considered adequate to ensure a 
homogeneous rating across sites. 
Clinical and safety assessments
Joints were assessed clinically for tenderness and swelling to calculate the TJC and 
SJC. In addition, American College of Rheumatology 20, 50, and 70 (ACR20, 50, and 
70) responses and their core components and the mean change from baseline in Health 
Assessment Questionnaire Disability Index (HAQ-DI) were evaluated. Safety 
assessments, including adverse events (AEs), serious AEs, and AEs of special interest 
occurring during the first 12 weeks, were performed in all patients receiving at least one 
dose of study drug.  
Statistical analysis
This study was designed to test the superiority of secukinumab compared with placebo 
at a 5% significance level with a two-sided test. No data applying the EULAR-
OMERACT composite PDUS score at the joint or patient level (GLOESS) in PsA were 
previously reported; however, the mean change from baseline to Week 12 was 
assumed based on the abatacept treatment effect from a previous PDUS study in RA 
[16]. Assuming a difference in the mean change from baseline to Week 12 in GLOESS 
(primary objective) of −6 with a pooled standard deviation of 13.2, a total of 218 patients 
(109 patients per arm) were estimated to achieve a power of 90%.
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Blinded sample size re-estimation (SSR) was performed after the completion of 
Week 12 for the first 60 patients and substantiated by data collection from the first 72 
enrolled patients to reassess variability of the disease and adjust sample size 
calculation accordingly. A protocol amendment was introduced to reduce the study 
sample size from 218 patients to 164 patients (82 patients per arm) with the power 
relaxed to 80% and a one-sided (α=5%) superiority test versus placebo for the primary 
objective. The detailed SSR has been provided in Supplementary Table S2, available at 
Rheumatology online. 
The efficacy analyses were performed on the full analysis set, which comprised 
all patients who were randomised and had study treatment assigned. The primary and 
key secondary endpoints were analysed according to a pre-defined statistical hierarchy 
(Supplementary Figure S3, available at Rheumatology online). The primary objective 
was to demonstrate a difference in mean change from baseline to Week 12 between 
secukinumab and placebo groups related to PDUS synovitis response using GLOESS 
(sum of the affected joints out of 48 joints). In addition, change between secukinumab 
and placebo from baseline to Week 12 in the core components (SH and PD signal) of 
GLOESS was analysed exploratory. The clinical exploratory outcome measures 
presented here include the proportion of patients achieving ACR70, the mean change 
from baseline in HAQ-DI score, and distribution of joints by ultrasound and clinical 
assessment at baseline.
Data presented for the secukinumab group were pooled data from 300 mg and 
150 mg. The primary analysis was performed using a mixed-effect model repeated 
measures (MMRM; valid under the “missing at random” assumption), with treatment 
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regimen, centre, and analysis visit as factors and weight and baseline GLOESS as 
continuous covariates. Treatment by analysis visit was included as an interaction term 
in the model. An unstructured covariance structure was assumed for this model. The 
significance of the treatment effect for secukinumab was determined using the 
comparisons performed between the secukinumab and placebo arms at Week 12. 
Missing values were imputed as non-response (non-responder imputation [NRI]) for 
binary variables via logistic regression, with study treatment as a factor and baseline 
weight as a covariate. Odds ratio and relative risk (for binary variables) or differences in 
adjusted mean change (for continuous variables) and 95% confidence interval (CI) are 
presented comparing secukinumab versus placebo. A “null zone” derived from the CI 
around the difference, obtained from the MMRM analysis, was plotted for continuous 
variables [17]. It shows the area where the means are located when there is no 
significant difference between the groups at the P<0.05 level.
Safety analyses included all patients who received ≥1 dose of study medication. 
AEs were reported as absolute frequencies over the placebo-controlled period, referring 
to the cumulative treatment period (i.e. events started after the first dose of study 
treatment or events present before the first dose of study treatment but increased in 
severity based on preferred term and on or before the last dose plus 84 days). The 
clinical and ultrasound response on enthesitis which were secondary and exploratory 
objectives are not included in the present report. 
RESULTS
Patient disposition and baseline characteristics
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Overall, 258 patients were screened, of whom 82 were ineligible for the study and 10 
were not included for other reasons (Figure 1). Out of 166 patients (64%) enrolled, 161 
(97%) completed the first 12 weeks (secukinumab, 99%; placebo, 95%; Figure 1). The 
proportion of patients with at least one protocol deviation was 15% (secukinumab, 16%; 
placebo, 13%; Supplementary Table S3, available at Rheumatology online). 
Demographics and baseline clinical characteristics were comparable between the 
treatment groups (Table 2). The mean age was 47 years, median disease duration was 
4 years, and 55% were women. Patients had active disease at baseline with a mean 
number of 14 tender joints, 9 swollen joints, and 4 clinically active enthesitis, as well as 
a mean Psoriasis Area and Severity Index score of 10. 
The average time spent on PDUS assessments at baseline for the evaluation of 
the pre-specified set of 24 paired joints was 39 minutes, for both the secukinumab and 
placebo arms. The distribution of PDUS synovitis revealed that wrists, knees, MCPs, 
and MTPs were the more frequently affected joints. A similar distribution was observed 
on clinical examination of swollen or tender joints with lower frequency. These data are 
presented in a heat map in Figure 2 and Supplementary Figure S4, Tables S4 and S5 
(available at Rheumatology online), respectively. 
PDUS efficacy
The primary endpoint was met at Week 12 (Figure 3); the adjusted mean (SE) change 
in GLOESS was significantly higher in the secukinumab versus placebo (−9 [0.9] versus 
−6 [0.9], difference [95% CI]: −3 [−6; −1]; one-sided P=0.004). A markedly significant 
difference between secukinumab and placebo was observed as early as 1-week after 
treatment initiation. The mean (SE) change from baseline to Week 12 in SH 
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(secukinumab versus placebo) was −9 (0.9) versus −6 (0.9) and in PD was −4 (0.5) 
versus −2 (0.5), with significance as early as Week 1 for SH and Week 2 for PD signal 
(Figure 3). 
Clinical efficacy
ACR20 and ACR50 responses were met and favored secukinumab-treated patients 
against placebo at Week 12, with significant improvements observed as early as Week 
1 for ACR20 and Week 2 for ACR50 compared with placebo (Figure 4). Significantly 
higher responses were observed in secukinumab-treated patients for the exploratory 
endpoints (ACR70 response and HAQ-DI score) at Week 12 compared with placebo 
(Figure 4). The mean changes from baseline to Week 12 in ACR core components are 
presented in Supplementary Table S6, available at Rheumatology online.
Safety
Overall, the incidence of treatment-emergent AEs up to Week 12 was 58% for the 
secukinumab group and 57% for the placebo group. The most frequent treatment-
emergent AEs in terms of crude incidence rates up to Week 12 were nasopharyngitis, 
hypertension, diarrhoea, headache, and latent tuberculosis in either secukinumab or 
placebo group. No serious AEs were reported in the secukinumab group. No deaths, 
serious infections, neutropaenia, major adverse cardiovascular events, inflammatory 
bowel disease, or malignancies were reported in either treatment group. Safety data are 
presented separately for individual treatment groups (secukinumab and placebo) in 
Supplementary Table S7, available at Rheumatology online.
DISCUSSION
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ULTIMATE is the first randomised, placebo-controlled, PDUS Phase III study in PsA 
that primarily aimed to address the effects of biological DMARDs on synovitis detected 
by a validated ultrasound outcome measurement instrument as a primary endpoint. The 
primary efficacy data of the ULTIMATE study showed a significant effect of 
secukinumab treatment compared to placebo in reducing active synovitis in PsA. This 
effect was observed as early as 1-week after the initiation of treatment and continued to 
improve at each time point of evaluation until Week 12. The ultrasound approach also 
allowed assessment of which aspects of synovitis improved first. Thus, the SH 
component showed the response as early as 1-week and the PD component as early as 
2 weeks after treatment initiation, highlighting a fast onset of efficacy of secukinumab in 
controlling inflammation in PsA.
To date, only one small observational study has suggested that DMARDs have 
an effect on synovitis in PsA. [18] Large controlled studies aiming to assess the direct 
effect of DMARDs on synovitis are lacking, despite the availability of objective 
instruments to measure such effects. ULTIMATE study revealed that the activity of 
synovitis in PsA, can be scored at patient level using a validated ultrasound scoring 
system (GLOESS). Moreover, the study showed that reliable assessment of synovitis in 
PsA is feasible across different centres. Thus, GLOESS was sensitive to detect 
decrease in synovitis across different ultrasound devices and examiners even without 
excluding patients with protocol deviations. The absence of a true reliability exercise 
among the examiners may be considered as a limitation. However, potential variability 
in ultrasound assessment related to expertise was minimised using a rigorous 
ultrasound training, an atlas with reference images and central reading of images of the 
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first patient enrolled across all sites. Possible remaining variability did not detract from 
the high sensitivity to change of GLOESS, which was developed to be sensitive across 
examiners and machines. Hence, these data suggest that assessment of synovitis by 
GLOESS is a reliable method to address the direct effect of DMARDs on synovitis in 
PsA.
The observed improvement in the signs and symptoms of PsA upon exposure to 
secukinumab confirmed its known clinical efficacy and was in accordance with earlier 
studies. Higher ACR responses were observed with secukinumab in the current study 
than in the secukinumab FUTURE 2 and FUTURE 5 studies [19, 20], possibly because 
of the uniquely rigorous combined clinical and ultrasound inclusion criteria on joints, and 
the stringent monitoring in this study over the initial 3 months. Treatment with 
secukinumab was well tolerated and the safety profile was consistent with the 
established safety profile across approved indications.[21]
 In conclusion, ULTIMATE is the first randomised study that evaluated the effect 
of DMARDs on PDUS measured synovitis as the primary endpoint. It demonstrated that 
secukinumab rapidly and significantly decreased synovitis, indicating a direct effect of 
IL-17 inhibition on the synovium in patients with PsA. As synovitis is critical for cartilage 
and bone destruction in PsA [1, 3, 4], these data also provide the basis for the observed 
protection of joint structure by secukinumab in patients with PsA. 
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Figure 1. Patient disposition through Week 12.
Screen failures are those who were screened but failed to meet the inclusion or met the 
exclusion criteria or met eligibility but did not move into treatment period 1 (i.e. the 
patient was not randomised; percentage is computed using the number of screened 
patients as the denominator).
N, total number of patients
Figure 2. Distribution of synovitis detected by ultrasound and, tender and swollen 
joints detected by clinical assessment at baseline.
The distribution of synovitis detected by ultrasound and distribution of tender and 
swollen joint detected by clinical examination at baseline side by side. Frequency of 
distribution varies from 0 to 80% (highest proportion of patients with ultrasound detected 
synovitis on wrist) and is visualised by a code of colour from yellow to red shown on the 
right bar. Grey colour means ultrasound did not assess synovitis of these joints.  
CMC, carpometacarpal; DIP, distal interphalangeal; MCP, metacarpophalangeal; MTP, 
metatarsophalangeal; PIP, proximal interphalangeal
Figure 3. PDUS efficacy outcomes through Week 12.
*P<0.05 versus placebo. (A) primary endpoint GLOESS (MMRM, difference [95% CI]:  –
3 [–6; –1], P=0.004) at Week 12; (B) GLOESS SH (MMRM, difference [95% CI]: –3 [–6; 
–1], P=0.004); and (C) GLOESS PD (MMRM, difference [95% CI]: –2 [–3; –1], 
P=0.001). The ‘null zone’ presented GLOESS scores was derived from the CI around 
the difference, which was obtained from the MMRM. It shows the area where the means 
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are located when there is no significant difference between the groups at the P<0.05 
level. 
EULAR, European League Against Rheumatism; GLOESS, Global OMERACT-EULAR 
Synovitis Score; LS, least squares; MMRM, mixed-effect model repeated measures; N, 
total number of randomised patients; n, number of evaluable patients; OMERACT, 
Outcome Measures in Rheumatoid Arthritis Clinical Trials; PD, Power Doppler; SEC, 
secukinumab; SH, synovial hypertrophy
Figure 4. Clinical efficacy outcomes through Week 12.
*P<0.05 versus placebo. (A) ACR20 response (NRI, odds ratio [95% CI]: 5 [2; 9], 
P<0.0001, relative risk: 2); (B) ACR50 response (NRI, odds ratio [95% CI]: 10 [4; 24], 
P<0.0001, relative risk: 5); (C) ACR70 response (NRI, odds ratio [95% CI]: 23 [3; 178], 
P=0.0013, relative risk: 18); and (D) HAQ-DI score (MMRM, difference: ‒0.5 [‒0.6; 
‒0.3]; P<0.0001). The ‘null zone’ presented HAQ-DI score was derived from the CI 
around the difference, which was obtained from the MMRM. It shows the area where 
the means are located when there is no significant difference between the groups at the 
P<0.05 level. 
ACR, American College of Rheumatology; HAQ-DI, Health Assessment Questioner 
Disability Index; LS, least squares; MMRM, mixed-effect model repeated measures; N, 
total number of randomised patients; NRI, non-responder imputation; n, number of 
evaluable patients; SEC, secukinumab








































































Table 1. Ultrasound scoring system for B-mode and PD signal at joint level
B-mode: Inflammatory or active Synovial Hypertrophy
Grade 0 No hypoechoic synovial thickening
Grade 1 Minimal hypoechoic synovial thickening 
filling the angle between the periarticular bones, without 
bulging over the line linking tops of the bones
Grade 2 Hypoechoic synovial thickening 
bulging over the line linking tops of the periarticular bones 
but without extension along the bone diaphysis
Grade 3 Hypoechoic synovial thickening 
bulging over the line linking tops of the periarticular bones 
and with extension to at least one of the bone diaphysis
PD signal
Grade 0 No flow (PD signal) in the synovium
Grade 1 Up to three single spots signals or up to two confluent 
spots 
or one confluent spot plus up to two single spots
Grade 2 Vessel signals in less than half of the area of the synovium 
(<50%)
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Grade 3 Vessel signals in more than half of the area of the synovium 
(>50%)
Grades: 0, normal joint; 1, minimal synovitis; 2, moderate synovitis; 3, severe 
synovitis. 
EULAR, European League Against Rheumatism; OMERACT, Outcome Measures in 
Rheumatoid Arthritis Clinical Trials; PD, Power Doppler; PDUS, Power Doppler 
ultrasonography
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Table 2. Baseline demographic and clinical characteristics
Characteristics§
Secukinumab 




Age (years) 47    (12) 47    (12)
Female, n (%) 45    (54) 46    (55)
Caucasian, n (%) 75    (90) 75    (90)
Time since diagnosis of PsA (years)                                                       6    (7)   7    (7)
TJC (78 joints) 13    (8) 15    (12)
SJC (76 joints) 10    (8)   9    (9)
Patient Pain (VAS) 59    (21) 59    (24)
Global assessment of disease activity (VAS)
Patient
Physician
60    (23)
56    (18)
60    (23)
52    (22)
HAQ-DI score   1.3   (0.6)   1.2    (0.7)
hsCRP level (mg/L), median (min–max)  7   (1‒77)   5    (0‒102)
PsO†, n (%) 36    (43) 33    (40)
PASI score†   9    (6) 11     (9)
GLOESS‡  24    (16) 27     (17)
SH 24    (16) 27     (17)
PD   8    (8)   7     (7)
Number of joints with PDUS synovitis   9    (5) 10     (5)
Concomitant corticosteroids, n (%) 13    (16) 19     (23)
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Concomitant methotrexate, n (%) 35    (42) 34     (41)
§mean (SD) unless otherwise specified; †calculated only for patients with BSA ≥3%; ‡24 paired 
joints
BSA, body surface area; GLOESS, Global EULAR-OMERACT Synovitis Score; HAQ-DI, health 
assessment questionnaire disability index; hsCRP, high sensitivity C-reactive protein; N, total 
number of randomised patients; OMERACT, Outcome Measures in Rheumatoid Arthritis 
Clinical Trials; PASI, Psoriasis Area and Severity Index; PD, Power Doppler; PDUS, Power 
Doppler Ultrasonography; PsA, psoriatic arthritis; PsO, psoriasis; SJC, swollen joint count; SH, 
Synovial hypertrophy; TJC, tender joint count; VAS, visual analog scale (range, 0–100)
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Figure 1. Patient disposition through Week 12. 
Screen failures are those who were screened but failed to meet the inclusion or met the exclusion criteria or 
met eligibility but did not move into treatment period 1 (i.e. the patient was not randomised; percentage is 
computed using the number of screened patients as the denominator). 
N, total number of patients 
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Figure 2. Distribution of synovitis detected by ultrasound and, tender and swollen joints detected by clinical 
assessment at baseline. 
The distribution of synovitis detected by ultrasound and distribution of tender and swollen joint detected by 
clinical examination at baseline side by side. Frequency of distribution varies from 0 to 80% (highest 
proportion of patients with ultrasound detected synovitis on wrist) and is visualised by a code of colour from 
yellow to red shown on the right bar. Grey colour means ultrasound did not assess synovitis of these joints. 
  
CMC, carpometacarpal; DIP, distal interphalangeal; MCP, metacarpophalangeal; MTP, metatarsophalangeal; 
PIP, proximal interphalangeal 
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Figure 3. PDUS efficacy outcomes through Week 12. 
*P<0.05 versus placebo. (A) primary endpoint GLOESS (MMRM, difference [95% CI]:  –3 [–6; –1], 
P=0.004) at Week 12; (B) GLOESS SH (MMRM, difference [95% CI]: –3 [–6; –1], P=0.004); and (C) 
GLOESS PD (MMRM, difference [95% CI]: –2 [–3; –1], P=0.001). The ‘null zone’ presented GLOESS scores 
was derived from the CI around the difference, which was obtained from the MMRM. It shows the area 
where the means are located when there is no significant difference between the groups at the P<0.05 level. 
EULAR, European League Against Rheumatism; GLOESS, Global OMERACT-EULAR Synovitis Score; LS, least 
squares; MMRM, mixed-effect model repeated measures; N, total number of randomised patients; n, 
number of evaluable patients; OMERACT, Outcome Measures in Rheumatoid Arthritis Clinical Trials; PD, 
Power Doppler; SEC, secukinumab; SH, synovial hypertrophy 
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Figure 4. Clinical efficacy outcomes through Week 12. 
*P<0.05 versus placebo. (A) ACR20 response (NRI, odds ratio [95% CI]: 5 [2; 9], P<0.0001, relative risk: 
2); (B) ACR50 response (NRI, odds ratio [95% CI]: 10 [4; 24], P<0.0001, relative risk: 5); (C) ACR70 
response (NRI, odds ratio [95% CI]: 23 [3; 178], P=0.0013, relative risk: 18); and (D) HAQ-DI score 
(MMRM, difference: ‒0.5 [‒0.6; ‒0.3]; P<0.0001). The ‘null zone’ presented HAQ-DI score was derived from 
the CI around the difference, which was obtained from the MMRM. It shows the area where the means are 
located when there is no significant difference between the groups at the P<0.05 level. 
ACR, American College of Rheumatology; HAQ-DI, Health Assessment Questioner Disability Index; LS, least 
squares; MMRM, mixed-effect model repeated measures; N, total number of randomised patients; NRI, non-
responder imputation; n, number of evaluable patients; SEC, secukinumab 
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